BTX has taken over substantially all the assets of Cell Targeting (CTI), Read more…
University of California, San Diego received $5.6M in grants Read more…
ATHX to sell 4,366,667 shares of its common stock and warrants Read more…
RENE.L it has reached a settlement with CUR regarding the existing litigation in the US between the parties. Read more…
Stem Cell companies survive or fail depending on their clinical trial advancement but, face IP risks far greater than in most other industries. Read more…
PSTI has priced a public offering of 11M units at a purchase price of $3.25 per unit Read more…
Essential thrombocythemia (ET or essential thrombocytosis) is a chronic blood disorder characterized by increased numbers of platelets in the blood. Read more…
STEM launched STEM24 and STEM133 … 2 antibody reagents that have utility for the isolation and detection of a range of different human cell types. Read more…
Cancer care may cost the US … 2/3’s more … in the next decade, potentially topping $200B as the population ages and drug prices rise. Read more…
A federal appeals court upheld a lower court’s dismissal of a lawsuit filed on behalf of all frozen human embryos in the US Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.